Leqembi to get third NICE appraisal committee meeting

6 March 2025

In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will convene a third appraisal committee meeting as part of its ongoing evaluation of Leqembi (lecanemab), the drug’s developers, Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) announced today.

The companies noted that lecanemab was authorized by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers on August 22, 2024.

The NICE continues to assess the cost-effectiveness of lecanemab and the associated costs of administering it to patients based on current National Health Service (NHS) services and capabilities.  Following discussions with Eisai and other patient, clinical and commissioning experts, the NICE has determined that further consultation is required before it finalizes its guidance. The NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time. However, a second consultation period has now begun which will conclude on March 27, 2025. The date of the third appraisal committee meeting is planned for May 14, 2025.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology